share_log

Nutex Health (NASDAQ:NUTX) Shares Gap Up to $1.74

Nutex Health (NASDAQ:NUTX) Shares Gap Up to $1.74

紐特士健康 (NASDAQ: NUTX) 股票差距高達 1.74 美元
Defense World ·  2023/01/13 04:32

Shares of Nutex Health Inc. (NASDAQ:NUTX – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $1.74, but opened at $1.79. Nutex Health shares last traded at $1.75, with a volume of 1,839 shares trading hands.

NUTEX 健康股份有限公司(NASDAQ:NUTX-獲取評級)的股票在周三交易之前就閃光了。該股票之前已收盤 1.74 美元,但收盤價為 1.79 美元。新泰健康股票最後成交價為 1.75 美元,成交量為 1,839 股。

Wall Street Analysts Forecast Growth

華爾街分析師預測增長

Separately, Benchmark began coverage on shares of Nutex Health in a research note on Friday, December 23rd. They issued a "buy" rating and a $3.00 price target on the stock.

另外,基準於 12 月 23 日(星期五)在一份研究報告中開始對 Nutex 健康的股份進行報導。他們發布了「買入」評級和 3.00 美元的股票價格目標。

Get
取得
Nutex Health
保健健康
alerts:
警報:

Nutex Health Stock Performance

新泰健康股票表現

The company has a debt-to-equity ratio of 1.73, a current ratio of 2.45 and a quick ratio of 2.38. The company's 50 day moving average is $1.60 and its 200 day moving average is $2.09.

該公司的債務與權益比率為 1.73,流動比率為 2.45,快速比率為 2.38。該公司的 50 日移動平均線為 1.60 美元,其 200 日移動平均線為 2.09 美元。

Nutex Health (NASDAQ:NUTX – Get Rating) last announced its quarterly earnings data on Monday, November 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $28.40 million for the quarter.
Nutex 健康 (NASDAQ: NUTX — 獲取評分) 上週一宣布了其季度收益數據,週一, 11 月 21 日.該公司報告了本季每股盈利(0.02 美元)。該業務本季度的收入為 28.40 萬美元。

Institutional Investors Weigh In On Nutex Health

機構投資者權衡 Nutex 健康

Large investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Nutex Health during the second quarter worth about $29,000. Cetera Investment Advisers bought a new position in shares of Nutex Health in the second quarter worth about $32,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Nutex Health in the second quarter worth about $36,000. Apollon Wealth Management LLC bought a new position in shares of Nutex Health in the second quarter worth about $49,000. Finally, Verition Fund Management LLC bought a new position in shares of Nutex Health in the second quarter worth about $52,000. 1.24% of the stock is currently owned by institutional investors and hedge funds.

大投資者最近買賣了該公司的股票。俄亥俄州斯特爾斯特斯在第二季度收購了 Nutex 健康的新股份,價值約為 29,000 美元。西泰拉投資顧問在第二季度購買了 Nutex 健康股份的新頭寸,價值約 32,000 美元。未來資產環球投資有限公司股份有限公司買了 Nutex 健康股份在第二季度的新頭寸,價值約 36,000 美元。阿波羅財富管理有限責任公司在第二季度購買了 Nutex 健康股份的新位置,價值約 49,000 美元。最後,威瑞基金管理有限責任公司在第二季度購買了 Nutex Health 股份的新頭寸,價值約為 $52,000 美元。1.24% 的股票目前由機構投資者和對沖基金擁有。

About Nutex Health

關於保泰健康

(Get Rating)

(取得評分)

Nutex Health, Inc operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments.

Nutex 健康有限公司是一家以技術為基礎的醫療保健服務公司。它通過兩個部門運作:醫院部門和人口健康管理部門。醫院部門實施和運營醫療保健模式,包括微型醫院、專科醫院和醫院門診部門。

Featured Stories

特色故事

  • Get a free copy of the StockNews.com research report on Nutex Health (NUTX)
  • Deere, Catepillar, PACCAR, Machinery Stocks You Need to Know
  • 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
  • Optimism About Global Demand For Metals Boosts BHP, Other Miners
  • Exxon Mobil Expects Earnings and Cash Flow to Grow
  • Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
  • 索取有關紐泰健康研究報告的免費副本
  • 您需要了解的迪爾,外來支柱,PACCAR,機械庫存
  • 3 種小型股生物製藥股票可能在 2023 年大增長
  • 關於全球對金屬需求的樂觀態度促進必和必拓,其他礦工
  • 埃克森美孚預計收益和現金流將增長
  • 索倫托治療學,希雷克斯:移動中的 2 熱製藥股票

Receive News & Ratings for Nutex Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutex Health and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Nutex 健康日報的最新消息和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Nutex Health 及相關公司的最新新聞和分析師評級的簡明每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論